Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ: CRNX · IEX Real-Time Price · USD
18.90
+0.01 (0.05%)
Oct 4, 2022 1:40 PM EDT - Market open
0.05%
Market Cap 1.06B
Revenue (ttm) 4.65M
Net Income (ttm) -135.65M
Shares Out 55.89M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,558
Open 18.99
Previous Close 18.89
Day's Range 18.78 - 19.65
52-Week Range 15.91 - 28.95
Beta 1.20
Analysts Buy
Price Target 43.86 (+132.1%)
Earnings Date Nov 3, 2022

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN... [Read more...]

Industry Biotechnology
IPO Date Jul 18, 2018
CEO R. Scott Struthers
Employees 143
Stock Exchange NASDAQ
Ticker Symbol CRNX
Full Company Profile

Financial Performance

In 2021, CRNX's revenue was $1.08 million, an increase of 1,418.31% compared to the previous year's $71,000. Losses were -$107.64 million, 45.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 43.86, which is an increase of 132.06% from the latest price.

Price Target
$43.86
(132.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Radionetics Oncology Appoints Umesh Gangadharmath, Ph.D. as Senior Vice President, Technical Operations

SAN DIEGO--(BUSINESS WIRE)--Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, ...

1 week ago - Business Wire

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global...

3 weeks ago - GlobeNewsWire

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Cong...

SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universida...

1 month ago - GlobeNewsWire

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the...

1 month ago - Zacks Investment Research

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Paltusotine's Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023

1 month ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics' Board of Directors granted n...

1 month ago - GlobeNewsWire

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of...

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional ...

2 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics' Board of Directors granted non...

2 months ago - GlobeNewsWire

Crinetics Presents Clinical and Research Results at ENDO 2022

CRN04894 Selected for Oral Presentation CRN04894 Selected for Oral Presentation

3 months ago - GlobeNewsWire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel thera...

3 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase ...

Patient Studies in Cushing's Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year

4 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel t...

4 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

5 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

5 months ago - GlobeNewsWire

Radionetics Oncology Appoints Nishan de Silva, M.D. as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, ...

5 months ago - Business Wire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 –

6 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion

6 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov...

6 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors

SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov...

6 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nov...

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and...

SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commerci...

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel thera...

7 months ago - GlobeNewsWire

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 –

8 months ago - GlobeNewsWire

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Co...

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of nove...

8 months ago - GlobeNewsWire

Does Crinetics Pharmaceuticals, Inc. (CRNX) Have the Potential to Rally 35% as Wall Street Analysts Expect?

The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

10 months ago - Zacks Investment Research